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Summary The endocrine effects of 125mg (low dose) aminoglutethimide (AG) twice daily (b.d.) were
compared with those of 125mgAG+20mg hydrocortisone (HC) b.d. in 23 and 45 postmenopausal patients
with advanced breast cancer, respectively. The patients in each group were drawn from two separate
populations, but the mean age and weight of the groups were similar and there were no significant differences
between the pretreatment serum levels of the hormones investigated. Serum oestrone and oestradiol levels
were suppressed by both treatments, but there was a significantly greater suppression by AG+HC. This
greater suppression is probably due to the observed increase in serum androstenedione (i.e. precursor) levels
with AG alone, whilst with AG+HC these levels were found to be reduced. In terms of suppression of serum
oestrogen levels it is of benefit to combine low dose AG with HC.
The clinical effectiveness of aminoglutethimide
(AG) in postmenopausal breast cancer patients was
initially thought to be due to its inhibition of the
adrenal 20,22 desmolase enzyme, which catalyses
the conversion of cholesterol to pregnenolone (Cash
et al., 1967). AG was therefore used with the aim of
achieving a 'medical adrenalectomy' (Lipton &
Santen, 1974; Smith et al., 1978; Wells et al., 1978)
in a dose of 750-1,000mgd-1 in combination with
hydrocortisone (HC, 40mgd-1). Oestrogen levels
are suppressed by AG+HC but it is now accepted
that the major, if not sole, mechanism by which
AG suppresses oestrogen levels is its potent
inhibition of peripheral aromatase, the enzyme
complex which converts circulating androgens to
oestrogens (Harris et al., 1983a; Nagel & Santen,
1984; Stuart-Harris et al., 1984, 1985). This has led
to a reassessment of the use of AG in breast cancer
patients. In particular, the recognition of the
greater potency of AG in vitro on the aromatase
than on the desmolase enzyme (Graves &
Salhanick, 1979) has led to an investigation of the
clinical use of lower dosages of AG than had
previously been used, without combination with
HC. We have previously identified 125mg twice
daily (b.d.) as being the lowest dose of AG which is
maximally effective in plasma oestrogen suppression
Correspondence: M. Dowsett
Received 26 April 1985.
c
(Harris et al., 1983a; Stuart-Harris et al., 1984,
1985) and this finding led to clinical trials
examining the effectiveness of this dose both with
and without HC (Cantwell et al., 1984; Stuart-
Harris et al., 1984). Blood samples from patients
from these two studies have been assayed to
determine the relative effectiveness of the treat-
ments in the suppression of postmenopausal
oestrogen levels.
Patients and methods
All patients had histologically proven, advanced
breast cancer and were either postmenopausal or
had undergone oophorectomy (time since last
menstrual period >2 years). No patient had
received endocrine therapy for at least 4 weeks
prior to treatment.
AG alone: Twenty-three patients at the Royal
Marsden Hospital, London were treated with
125mgAGb.d. The mean age of the patients was
61.2+2.1 (s.e.) years and the range was 45-82.
Their mean weight was 66.0+2.3kg and the range
was 52-92.
AG+HC: Forty-five patients at the General Hospi-
tal, Newcastle were treated with 125mgAGb.d.
and 20mgHCb.d. Their mean age was 63.0+1.6
years and the range was 38-83. Their mean weight
was 63.0+ 1.8kg and the range was 43-98.
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Blood samples were collected at outpatient clinics
from patients before and at monthly intervals
during treatment, at the same time of day for each
patient. Serum was stored at -20°C until analysis.
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Serum hormone levels
Serum levels ofoestrone, oestradiol, androstenedione
and dehydroepiandrosterone sulphate (DHAS) were
measured by previously described assays (Harris et
al., 1982 [DHAS] and 1983b [oestradiol]; Dowsett
et al., 1984 [androstenedione]; Stuart-Harris et al.,
1985 [oestrone]). All samples from each patient were
assayed in the same batch but the inclusion of
patients from each group in a particular batch was
randomised.
Results
There was no significant difference between the two
treatment groups in either the mean age or weight
of the patients. As treatment progressed patients
who did not respond or who relapsed were with-
drawn and there were therefore less samples
available for analysis. For this reason the
comparison of endocrine effects was made between
samples taken before and after 1, 2, 3-4, 5-6 and
>6 months treatment. If more than one sample
was available during any of the intervals the mean
value was calculated and used for comparison.
The mean levels of oestrone, oestradiol,
androstenedione and DHAS before and during
treatment are shown for both groups in Figure 1.
The two treatment groups had similar levels of the
four analytes initially except for oestradiol where
the AG group had a higher mean level (61.7+10.2
[s.e.] vs. 48.4+6.3pmol - 1) although this was not
statistically significant. For both groups one month
after starting treatment the mean values of all 4
analytes were significantly different from pre-
treatment values (f-test, P<0.02 all cases). Mean
levels were suppressed in all cases except for
androstenedione which in the AG only group
increased by up to 90%. After the first month there
was little further change in the mean levels of the
analytes, although in the AG alone group oestrone
levels showed a further fall of marginal significance
(f-test, P=0.05) between months 1 and 2.
At one month the mean levels of all analytes
were lower in the AG+HC than the AG alone
group. This difference was statistically significant
(P<0.01) for all analytes except oestradiol
(P=0.07). The effects of the two treatments over
the entire study period was tested by an analysis of
variance (repeated measures design). For oestrone,
androstenedione and DHAS, suppression was
significantly greater with AG+HC (P<0.01), but
.5 E
0.
._
n U) W
0
L
=5
E
C
0)
c
0
:5
iE
0)
c
0)
c0
0
E
C,)
0n
100o
50
60-
40-
20-
8r
6
4
2
- 23
29\
- 02 14 1 -\ t g 8~~~~
25 25 25 21 15
- 23
40 19 20 14 12
8 8
3735 12
- 20 22 13 12
23 8
36\31 27
9 10 9
Pre 1 m 2 m 3-4 m 5-6m >6m
Months on treatment
Figure 1 Mean (±s.e.) serum levels of oestrone,
oestradiol, androstenedione and DHAS, before and
during treatment with 125mgAGb.d. alone (0) or in
combination with 20mgHCb.d. (0). The number of
samples available at each time point is indicated.
there was no significant difference between the
treatments in their effects on the levels of
oestradiol.
Since pretreatment oestradiol levels were different
between the two groups, the suppression of
oestradiol as a percentage of pretreatment level was
compared between the groups (Figure 2). Through-
out the study the mean value in the AG+HC
group varied within the range of 35-45% of
of baseline, whilst in the AG alone group the values
remained between 50 and 60% (except at 3-4 months
where a single value of 240% markedly raised the
mean and exclusion of that value gave a mean of
59.2%). The levels at 1 month were significantly
different between treatment groups (t-test, P<0.01)
and an analysis of variance showed a significantLOW DOSE AMINOGLUTETHIMIDE 527
a)
E
0~ ~~2
1im 2 m 3-4 m 5-6m >6 m
Months on treatment
Figure 2 Mean (±+s.e.) serum levels of oestradiol as a
percentage of pretreatment levels, before and during
treatment with 125mgAGb.d. alone (0) or in
combination with 20mg HC b.d. (0). The number of
samples available at each time point is indicated.
difference between the 2 treatments throughout the
study (P= 0.04). The suppression of oestrone and
oestradiol as a percentage of baseline, 2 months
after starting treatment, is compared in Table I
with the suppression found in our two previous
endocrine studies, where there was no significant
difference in suppression of either oestrogen
between 250mg AG and 1,000mg AG + 40mg HG
daily.
Discussion
The observation that the side effects of AG are
dose-related (Murray et a!., 1979; Harris et a!.,
1983b) makes it desirable to use the lowest,
clinically effective dose. We have previously found
no significant difference in oestrogen suppression
between daily administration of 250mgAG alone
and 1,000mgAG either alone or combined with
40mgHC (Harris et al., 1983a; Stuart-Harris et al.,
1985). This study aimed to determine whether
combination of low dose AG with HC would be
beneficial in terms of greater oestrogen suppression
than low dose AG alone.
The treatment of patients in this study was not
randomized and the 2 groups were derived from
geographically separate populations. It was there-
fore important to determine if any characteristic of
the patients which might have been expected to
affect endocrine status or changes to that status
was different between the groups. The factors which
have been most clearly delineated as being related
to aromatase activity and plasma oestrogen levels
in postmenopausal women are age and weight
(Grodin et al., 1973; James et al., 1981; Cleland et
al., 1985). In the present study these factors were
similar in the two groups. The lack of significant
difference between the groups in the pretreatment
levels of the analytes also supports the com-
parability of the groups.
Oestrone levels were clearly suppressed to a
greater extent by AG +HC than AG alone. It is
probable that this relates to the respective changes
in the levels of androstenedione, a substrate for
peripheral aromatisation and the immediate precur-
sor of oestrone, which occurred in the two treatment
groups. The levels are increased on the group
treated with AG alone, probably because of its
inhibition of the 11- and 21-hydroxylases (Harris et
al., 1983a). Combination of HC with 1,000mgAG
daily has previously been shown to have little effect
Table I Serum oestrone and oestradiol concentration as % of baseline in postmenopausal women with
advanced breast cancer, treated with different doses of aminoglutethimide with and without
hydrocortisone (HC).
% ofbaseline
Oestrone Oestradiol
Daily dose of Studya Studyb Presentc Studya Studyb Present'
aminoglutethimide I II study I II study
250mg 50.2+6.4 73.7+5.9 64.6+5.3 52.3 + 14.5 69.8+ 13.5 57.6+ 5.8
(13) (25) (22) (13) (22) (20)
250mg+40mgHC 49.6+3.6 44.0+4.7
(25) (35)
1,000mg+40mgHC 49.4+8.3 63.6+7.1 41.4+16.9 54.5+ 13.3
(8) (18) (8) (16)
aStudy I - Harris et al., 1983a; bStudy II - Stuart-Harris et al., 1985; cPresent study - values after 2
months treatment. Figures in brackets indicate the number of patients on each treatment.528 M. DOWSETT et al.
on androstenedione levels (Samojlik et al., 1980;
Harris et al., 1983a, 1984), but in this study com-
bination with low dose AG led to a marked sup-
pression. AG at a dosage of 125mgb.d. reduces
peripheral aromatoase activity by 92% (Dowsett
et al., 1985). It seems likely that the small residual
activity combined with an increase in precursor
levels as occurs with AG alone, resulted in the less
marked suppression of oestrone in that group. It is
probable that the effect on oestradiol levels was
greater with AG+HC, although statistically this
could be shown only after conversion of the values
to percentages of pretreatment level.
Consideration of the current results and those of
our previous reports, which indicated no significant
difference in oestrogen suppression between
250mgAG alone and 1,000mgAG+40mgHC
daily (Harris et al., 1983a; Stuart-Harris et al.,
1985), might lead to the suggestion that
250mgAG+HC may be more effective than
1,000mgAG+HC in this respect. However, it is
probable that this is not the case since in the earlier
studies there was a trend towards greater oestrogen
suppression by the higher dose with HC (as shown
in Table I) although this was not statistically
significant. In addition, the suppression found in
the present study was no greater than that found
for either oestrogen in patients on treatment with
1,000mgAG+HC in our first study of low dose
AG (Harris et al., 1983a).
In much of the work on the endocrine effects of
AG+HC, DHAS has been used as a marker of
adrenal androgen activity. The results of this study
show a marked non-parallelism in the changes in
DHAS and androstenedione levels, particularly in
the group treated with AG alone. This is probably
a reflection of the effects of AG on cytochrome
P450 mediated steroidogenic enzymes other than
the 20,22 desmolase (Santen et al., 1981) and it
indicates that DHAS is not necessarily a useful
marker of adrenal androgen secretion.
In conclusion, the difference in the levels of both
oestrogens between the two treatment groups
indicates that the combination of HC with low dose
AG is beneficial in attempting to achieve maximal
oestrogen suppression, and may be significant in
determining the efficacy of low dose AG in the
suppression of oestrogen-dependent breast cancer
growth.
The statistical analyses were kindly performed by Miss
Janice Barnes, Ciba Geigy, Horsham.
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